AGN - Allergan plc

NYSE - NYSE Delayed price. Currency in USD
173.60
+1.10 (+0.64%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous close172.50
Open172.65
Bid173.64 x 800
Ask173.81 x 900
Day's range172.65 - 174.62
52-week range114.27 - 190.36
Volume3,362,757
Avg. volume3,275,409
Market cap56.958B
Beta (3Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)-25.50
Earnings date5 Nov 2019
Forward dividend & yield2.96 (1.74%)
Ex-dividend date2019-08-12
1y target est183.40
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
    Zacks

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

  • Editas Inks Deal for Gene Editing Neurological Disease Drugs
    Zacks

    Editas Inks Deal for Gene Editing Neurological Disease Drugs

    Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.

  • 'High-level dope dealers': Democratic candidates sound off on big pharma
    Yahoo Finance

    'High-level dope dealers': Democratic candidates sound off on big pharma

    Democratic candidates like Kamala Harris and Amy Klobuchar criticized big pharma companies for their role in the opioid crisis.

  • Allergan (AGN) Shareholders Approve Acquisition by AbbVie
    Zacks

    Allergan (AGN) Shareholders Approve Acquisition by AbbVie

    Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

  • Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors
    Zacks

    Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

    Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

  • Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
    Zacks

    Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

    Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

  • Wet AMD Space in Focus: New Drug Approvals & Key Advancements
    Zacks

    Wet AMD Space in Focus: New Drug Approvals & Key Advancements

    The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

  • J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
    Zacks

    J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

    J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

  • Allergan (AGN) Stock Moves -1.09%: What You Should Know
    Zacks

    Allergan (AGN) Stock Moves -1.09%: What You Should Know

    In the latest trading session, Allergan (AGN) closed at $166.46, marking a -1.09% move from the previous day.

  • IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
    Zacks

    IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

    IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

  • Allergan (AGN) Stock Moves -0.1%: What You Should Know
    Zacks

    Allergan (AGN) Stock Moves -0.1%: What You Should Know

    In the latest trading session, Allergan (AGN) closed at $166.69, marking a -0.1% move from the previous day.

  • The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan
    Zacks

    The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan

    The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan

  • Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
    Zacks

    Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet

    Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet

  • GlobeNewswire

    SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – AGN, ORIT, MCRN, GHDX

    The investigation concerns whether Allergan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Allergan to AbbVie Inc. Under the terms of the proposed transaction, Allergan shareholders would receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share. If you are an Allergan shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/allergan-plc-agn-stock-merger-abbvie/.

  • FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)
    Zacks

    FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)

    As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

  • Ironwood Amends Linzess Agreement with AstraZeneca in China
    Zacks

    Ironwood Amends Linzess Agreement with AstraZeneca in China

    Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.

  • Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Algernon Pharmaceuticals Inc.'s (CNSX:AGN) Investor Composition Influence The Stock Price?

    The big shareholder groups in Algernon Pharmaceuticals Inc. (CNSX:AGN) have power over the company. Insiders often own...

  • Allergan (AGN) Dips More Than Broader Markets: What You Should Know
    Zacks

    Allergan (AGN) Dips More Than Broader Markets: What You Should Know

    Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.

  • Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
    Zacks

    Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

    Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

  • Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
    Zacks

    Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

    Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

  • Bloomberg

    Opioid Deal-Makers Cleared to Represent Cities Across U.S.

    (Bloomberg) -- A judge approved a bid by U.S. cities and counties suing opioid makers such as Johnson & Johnson and Teva Pharmaceutical Industries Ltd. to negotiate a settlement as a group, in an effort to resolve the sweeping litigation over the addictive painkillers.U.S. District Judge Dan Polster in Cleveland, overseeing more than 2,000 lawsuits by municipalities, concluded that the negotiation class was necessary to reach a resolution acceptable to plaintiffs and opioid makers and distributors. The class is meant to bring together more than 30,000 U.S. municipalities, most of which haven’t yet filed suit.In a 40-page ruling, Polster said he was willing to back the “novel” idea of establishing a class before a negotiating framework is in place in order to speed a settlement that expedites “relief to communities so they can better address this devastating national health crisis.”The ruling comes as Purdue Pharma LP is nearing a $12 billion deal to settle claims it illegally marketed opioid painkillers, according to people familiar with the talks. Twenty-three states and three territories told the court Wednesday they’d support a plan under which the billionaire Sackler family, which owns Purdue, would file for bankruptcy protection and hand over the drugmaker to a trust controlled by the states, cities and counties that have sued.The $12 billion deal would cover only Purdue. But the two, parallel sets of talks going on -- one set including 48 states and the other the municipalities -- are global, including opioid distributors such as McKesson Corp. and Cardinal Health Inc. as well as manufacturers.Read More: Purdue Nears Deal Over Opioids as 23 States Agree to PactMore than 30 states opposed the local governments’ push to set up the negotiating class, saying it was too early for such a move and would interfere with their efforts to reach an overarching resolution of all suits. The class is a “novel procedure that could result in a grave miscarriage of justice and do significant harm to the ability of states to protect their own people,” Attorney General Ken Paxton of Texas said in a letter to Polster.The judge tapped plaintiffs’ lawyers including Jayne Conroy and Christopher Seeger as the class’s lead attorneys for the negotiations. Joe Rice, Paul Hanly and Paul Farrell are overseeing the cities and counties’ case as a whole.The approval of the class will let plaintiffs “use their joint bargaining power to secure the resources they need to fund addiction, recovery, and prevention efforts in their own neighborhoods,” Conroy and Seeger said in a statement. They said it would empower the plaintiffs “without inhibiting other ongoing litigation and settlements at the state, county, or local levels.”McKesson and Teva representatives declined to comment on the class’s approval. Jessica Castles-Smith, a J&J spokeswoman, didn’t immediately respond to phone and email messages seeking comment. Brandi Martin, a Cardinal Health spokeswoman, didn’t immediately respond to emails seeking comment.Read More: Sacklers to Remain Billionaire Family If Deal Is ReachedThe class, which cities and counties can escape only by filing an opt-out notice, will negotiate with more than a dozen opioid distributors and makers, along with some pharmacy chains, Polster said.The plaintiffs accuse the industry of conducting illegal marketing campaigns, failing to adequately oversee orders and ignoring red flags about unusually frequent retail sales. Almost 400,000 people died from opioid overdoses in the U.S. from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.Some defendants involved in the talks have already agreed to settle claims rather than face a Cleveland jury next month in the first federal trial over responsibility for the U.S. opioid epidemic.Mallinckrodt Plc, a generic-opioid maker, agreed this month to pay $30 million to settle allegations it helped fuel the opioid epidemic and to resolve claims it faced in the Oct. 21 Cleveland trial. Last month, Endo International Plc’s units agreed to an $11 million settlement, while Allergan Plc signed off on a $5 million deal.The case is In Re National Prescription Opioid Litigation, 17-md-2804, U.S. District Court, Northern District of Ohio (Cleveland).(Updates with McKesson declining to comment.)To contact the reporter on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.netTo contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Peter Jeffrey, Steve StrothFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
    Zacks

    Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

    The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

  • Allergan (AGN) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Allergan (AGN) Outpaces Stock Market Gains: What You Should Know

    Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session.

  • The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
    Zacks

    The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

    The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

  • ETFs Poised to Benefit from Gene Editing Revolution
    Zacks

    ETFs Poised to Benefit from Gene Editing Revolution

    Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.